Accueil   Diary - News   All news MaaT Pharma completes patient recruitment of its Odyssée clinical trial

MaaT Pharma completes patient recruitment of its Odyssée clinical trial

Within thirty months of its creation, Maat Pharma has reached the target number of patients to be treated in its first clinical trial, Odyssée. The biotech is testing the efficacy of its drug candidate, MaaT001.3, using Autologous Fecal Microbiota Transfer on patients suffering from Acute Myeloblastic Leukemia. The end of the recruitment phase positions MaaT Pharma as one of the most advanced companies in the promising Microbiome industry.

 

 

Lyon (France), 20th July 2017 – MaaT Pharma, a European MicrobioTech[1] specialized in the development of innovative treatments based on intestinal microbiota in onco-hematology and infectiology, announces recruitment completion of its Odyssée study using MaaT001.3, an internally developed experimental drug.

 

 

The clinical study is a multi-centric trial conducted in France on patients with Acute Myeloblastic Leukemia (AML). These patients suffer from iatrogenic dysbiosis induced by chemotherapy and / or antibiotics. The candidate drug, MaaT001.3, is administered to patients once their treatment against leukemia has ended. Reconstitution of the intestinal microbiota is evaluated 10 days after the Autologous Fecal Microbiota Transfer (FMT), which is the primary endpoint of the Odyssée clinical trial.

 

 

 

 

Read the press release